Sapreme Technologies
Sapreme Technologies is Enabling endosomal escape of macromolecule therapeutics.
Total raised
€22M
€21,800,000
Funding rounds
2
Investors
3
distinct backers
Active since
2018-12
latest 2021-10
Funding by year
EUR raised per yearSignals
High confidenceRaise-next likelihood18
base rate 44% for Series A
- ▼ Dormant (no round in 3+ cohort gaps)
- ▲ Up-round momentum
- ▼ Low backer re-investment
Exit likelihood13
base rate 12% (2+ rounds)
- ▲ 10y since founding
Timing: dormant vs cohort gap · momentum up. Funding-only estimates, not predictions and not investment advice — see signals.
Funding rounds
2 rounds| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2021-10-11 | Series A | €15M | Aglaia Oncology Funds,Private Investors | View deal → |
| 2019-01-01 | Other | €6.8M | Horizon 2020 | View deal → |
Related news
- Dutch biotech company Sapreme raises €15M to develop therapies to treat cancer; know more heresiliconcanals.com · 2021-10
- finsmes.com
Similar companies
same sector or country- Philips€2.6BNetherlands · Healthtech
- Isomorphic Labs€2.3BUK · Healthtech
- Picnic€1.7BNetherlands · E-commerce
- Just Eat Takeaway€1.6BNetherlands · Foodtech
- Nebius€1.5BNetherlands · Cloud
- Roivant Sciences€1.2BSwitzerland · Healthtech